Zoono Group (ZNO.AX) Stock Price

Zoono Group Price

ASX·CLOSED
0.05
​
Market closed

Over the last 19 years Zoono Group grew revenue by 0.1% annually, reaching 1.49 M NZD. Earnings per share have declined at 30.9% per year over the last 11 years. For Zoono Group, the net margin of -107.0% is up versus -126.4% a few years ago. At today's price the dividend yield works out to roughly 0.66%. The payout ratio is around 0% of earnings.

Zoono Group stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zoono Group business model & stock analysis

The Zoono Group Ltd is a globally operating company that develops and distributes antimicrobial solutions. The company was founded in New Zealand in 2009 and now has branches and distribution partners in Australia, USA, Canada, Europe, Asia, and South Africa. The business model of Zoono is based on the development and marketing of antimicrobial solutions for use in various industries, such as healthcare, food industry, animal husbandry, and public buildings. The goal of Zoono is to provide a safe and effective alternative to conventional cleaning and disinfection methods. Zoono's products contain special molecules that adhere to surfaces and form a barrier against bacteria, viruses, fungi, and algae. Some of Zoono's products include hand disinfectants, surface disinfectants, air purifiers, and pet care products. The company places a strong emphasis on ensuring that these products are non-toxic, biodegradable, and environmentally friendly. Zoono's solutions have already proven themselves in various industries. For example, they are successfully used in the food industry to prevent the growth of bacteria and mold. The products are also used in healthcare settings because of their long-lasting effectiveness, reducing the risk of infections. In addition to antimicrobial solutions, Zoono also offers consulting services. The company develops individual solutions for customers and adapts the products to meet specific requirements and needs. Thanks to the high effectiveness of their products, extensive network of partners and customers, and constant innovation of new solutions, Zoono has established itself as a successful and forward-thinking company in the industry. In conclusion, the Zoono Group Ltd is an innovative and internationally operating company specializing in the development and marketing of antimicrobial solutions. Their business model is based on the development of safe and effective alternatives to conventional cleaning and disinfection methods. Thanks to the high effectiveness of their products and extensive network of partners and customers, Zoono has established itself as a leading provider in the industry.

Frequently asked questions about Zoono Group

The business model of Zoono Group Ltd revolves around the development, manufacture, and distribution of a range of antimicrobial solutions. Zoono Group focuses on creating and marketing innovative long-lasting disinfectant products for various applications, including commercial, industrial, and personal use. Their scientifically advanced formulations provide a protective barrier against harmful microbes, delivering extended germ protection. Zoono's products have gained recognition for their effectiveness, durability, and environmentally friendly features. As a leading company in the antimicrobial industry, Zoono Group Ltd continually strives to enhance their product portfolio and expand their global presence.

Zoono Group Ltd is primarily active in the industries of biotechnology, consumer goods, and healthcare.

The main competitors of Zoono Group Ltd in the market include companies such as Microban International, Clorox Company, Reckitt Benckiser Group plc, and 3M Company.

Zoono Group Ltd is a leading company that specializes in the development and production of long-lasting antimicrobial solutions. Established in New Zealand, the company was founded in 2008 and has since expanded its operations globally. Zoono's innovative technology utilizes a unique bonding process that forms a protective barrier capable of eliminating a wide range of bacteria, viruses, and fungi. With a strong commitment to research and development, Zoono has continuously evolved its product offerings, including hand sanitizers, surface sprays, and other disinfecting solutions. Today, Zoono Group Ltd is recognized as a trusted provider of safe and effective antimicrobial protection worldwide.

Zoono Group Ltd, a leading company in the antimicrobial industry, has achieved several significant milestones. Firstly, Zoono gained global recognition for its innovative and highly effective antimicrobial technology, which provides long-lasting protection against a wide range of pathogens. Additionally, the company successfully expanded its product range, catering to various industries including healthcare, consumer, and industrial sectors. Zoono Group Ltd also established strong partnerships with renowned organizations worldwide, enhancing its market presence and distribution capabilities. Furthermore, the company's shares have been listed on prestigious stock exchanges such as the Australian Securities Exchange (ASX) and the London Stock Exchange (LSE), providing investors with increased opportunities. Overall, Zoono Group Ltd has consistently demonstrated its commitment to pioneering antimicrobial solutions and achieving remarkable business growth.

Zoono Group Ltd is primarily present in several countries and regions worldwide. These include Australia, New Zealand, the United Kingdom, Europe, the United States, Canada, Asia, and the Middle East.

Zoono Group Ltd represents a core set of values and a strong corporate philosophy. As a company, Zoono is committed to innovation, transparency, and sustainability. It values continuous improvement and strives to deliver high-quality products and services to its customers. Zoono Group Ltd believes in building strong relationships with stakeholders, including employees, customers, and partners, based on trust and mutual respect. The company's philosophy revolves around responsible business practices, ethical decision-making, and fostering a positive and inclusive work environment. Zoono Group Ltd aims to make a positive impact on society by providing effective and safe antimicrobial solutions.

Converted at the current exchange rate, the Zoono Group share trades at 0.02 EUR (0.05 NZD).

The Zoono Group share (ZNO.AX) is listed on 2 stock exchanges, including: ASX (ZNO.AX).

The company Zoono Group Ltd is a specialist in antimicrobial technologies and offers products and services in various areas. The company is based in New Zealand and operates globally. Zoono's core business offers various antimicrobial solutions based on quaternary ammonium compounds and silver ions. These technologies effectively fight bacteria, viruses, and fungi, reducing the risk of infections. Zoono's business model involves developing, manufacturing, and distributing these technologies. One of Zoono's crucial sectors is the production of products for use in medicine. This includes antiseptic solutions for skin and hand disinfection, as well as wound disinfectants. These products are particularly crucial in hospitals and other medical facilities, where the spread of infections is a significant problem. Another important area in which Zoono operates is the food industry. This includes antimicrobial coatings for packaging and surfaces in food facilities to prevent the growth of bacteria and mold and extend the shelf life of food. Zoono also offers solutions for air and surface disinfection. Zoono's technologies can be used in ventilation systems, air conditioning, and rooms to reduce the spread of bacteria and viruses, thereby minimizing the risk of infection. Furthermore, Zoono offers products for personal use. This includes deodorants, mouthwashes, and hand sanitizers. These products are also intended for use by the general public and aim to reduce the overall risk of infection in society. Recently, the company has also begun to bring its antimicrobial technologies into the field of animal care. This includes antimicrobial dog protection products and products for disinfecting animal shelters and veterinary clinics. In summary, Zoono's business model involves developing, manufacturing, and distributing antimicrobial technologies. The company operates in various areas and sectors, including medicine, the food industry, air and surface disinfection, personal use, and animal care. By providing these products and services, Zoono helps reduce the risk of infection and improve the health and safety of humans and animals.

The revenue of Zoono Group is 1.49 M NZD. This figure is based on current financial data and reflects the company's business performance.

The profit of Zoono Group is -1.59 M NZD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zoono Group is currently -11.56. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zoono Group stock.

The price-to-sales ratio (P/S) of Zoono Group is currently 12.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zoono Group stock.

The Eulerpool Quality Score for Zoono Group is 3/10.

The ISIN of Zoono Group is AU000000ZNO4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Zoono Group is A2PZCA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Zoono Group is ZNO.AX. The ticker symbol is used to trade Zoono Group shares on the stock exchange.

Fair ValueTerminal
0.04 NZD
Over-/UndervaluationTerminal
Fairly valued
Industry
Chemicals
Number of shares
Employees
Revenue per Employee
744,163.00 NZD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
NZD
Initial public offering
Jul 21, 1988
ISIN
AU000000ZNO4
Cusip
Q989BT100
Sedol
BD370Q4
Market capitalization
16.28 M NZDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
5.60
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-49.65 %
Dividend
Dividend yield
0.00 %
Payout Ratio
0.31 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Nov 21, 2026, 5:24 PM

Zoono Group Ticker

ASX · ZNO.AXOTC · ZOONF

Zoono Group FIGI

ZNO:AU · BBG000BQ5TN5ZNO:AT · BBG000BQ5TW5ZOONF:US · BBG000CXYVB5ZNO:AH · BBG002F3FLS9ZOONF:PQ · BBG002JF6ST2ZOONF:UV · BBG002JF6SW8

All fundamentals and in-depth analysis of Zoono Group

Our stock analysis for Zoono Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zoono Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.